Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Breast cancer drug gets FDA priority review

The U.S. drug regulator will give a speedy review to AstraZeneca Plc’s experimental breast cancer treatment trastuzumab deruxtecan.

Read More »

New System Hunts Down Cancer Cells that Hide from Immunotherapies

Yale University researchers developed a new system dubbed Multiplexed Activation of Endogenous Genes as Immunotherapy (MAEGI) that hunts down cancer cells.

Read More »

More Research Links Immune Cells to Alzheimer’s Disease

Researchers at Washington University School of Medicine in St. Louis found further evidence that microglia are the key link between the accumulation of abnormal proteins, including beta-amyloid and tau, in the brain and the actual brain damage observed in Alzheimer’s patients.

Read More »

FDA Approves Labeling Supplement for Puma Biotechnology’s Breast Cancer Drug Nerlynx

Puma Biotechnology Inc. announced that the U.S. Food and Drug Administration approved a labeling supplement for Nerlynx (neratinib) for the extended adjuvant treatment of HER2-positive early stage breast cancer.

Read More »

Genentech’s Tecentriq Improves OS as First-line Monotherapy in Certain People With Advanced NSCLC

Genentech announced positive data from the Phase III IMpower110 study evaluating Tecentriq as a first-line monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).

Read More »

Are Drugmakers Going After the Right Targets in Cancer Cells?

Researchers from Cold Spring Harbor Laboratory in New York discovered that certain proteins believed essential for the survival of cancer cells – the same proteins that many drugmakers have been targeting – may not be as important after all.

Read More »

GSK to Acquire Celiac-Focused Sitari Pharmaceuticals

GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease.

Read More »

AstraZeneca Bolsters Machine Learning for Drug Development with Schrödinger Deal

AstraZeneca struck a deal to use Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.

Read More »

AbbVie abandons late-stage lung cancer asset Rova-T

AbbVie Inc. will cease to develop the experimental drug Rova-T after failing to show survival benefit in a late-stage trial for a type of lung cancer.

Read More »

Abbott Blood Test Can Detect Concussions that CT Scans Missed, Study Shows

One of the largest concussion studies ever conducted found that a new blood test developed by Abbott was able to detect a protein in the blood that confirmed a concussion, even if the result of a CT scan came back negative.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom